{"ctNumber":"2024-519412-13-00","ctStatus":"Authorised","startDateEU":"2026-09-02","decisionDate":"2026-02-18T18:26:44.216","publishDate":"2026-09-11T03:37:35.106699972","ctPublicStatusCode":3,"authorizedApplication":{"authorizedPartI":{"id":129561,"rowSubjectCount":25,"rowCountriesInfo":[{"eutctId":100000000557,"name":"United States","isoNumber":840,"isoAlpha2Code":"US","isoAlpha3Code":"USA","current":true}],"products":[{"id":538112,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11718547","productPharmForm":"SOLUTION FOR INJECTION","euMpNumber":"PRD11718547","prodAuthStatus":1,"prodName":"rAAV-Olig001-ASPA","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"CIRACIGENE GOLPARVOVEC","euSubstNumber":"SUB284340","productOtherName":"ciracigene golparvovec","nameOrg":"MYRTELLE, INC.","productSubstances":[{"productPk":"11718547","substancePk":"404900","nameOrg":"MYRTELLE, INC.","substanceOrigin":"Structurally Diverse Substance - Other","actSubstOrigin":"Structurally Diverse Substance - Other","actSubstName":"CIRACIGENE GOLPARVOVEC","substanceEvCode":"SUB284340","synonyms":["MYR-101","Recombinant adeno-associated virus Olig001 containing human aspartoacylase cDNA","rAAV-Olig001 containing human ASPA cDNA"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/22/2729","evCode":"PRD11718547","sponsorProductCodeEdit":"MYR-101","therapies":[{"id":6861,"catReferenceNumber":"EMA/CAT/638421/2022","advancedTherapyType":"3","geneOfInterest":"ASPA","description":"The product contains recombinant adeno- associated virus capsid and a genetic component containing the human ASPA cDNA (rAAV- ASPA).","isGmo":false,"isInVivo":true,"geneTransferProductType":"3"}],"devices":[],"characteristics":["8"],"routes":["INTRACEREBROVENTRICULAR (ICV)"],"allSubstancesChemicals":false,"productName":"rAAV-Olig001-ASPA","jsonActiveSubstanceNames":"ciracigene golparvovec","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of rAAVOlig001-ASPA Gene Therapy for Treatment of Children with Typical Canavan Disease","fullTitleTranslations":[{"id":10795817,"uuid":"20494060-fe97-4ce5-8608-97b80c9b2770","attributeTranslation":"Étude de phase 1/2, en ouvert, à dose unique évaluant une thérapie génique par rAAVOlig001-ASPA administrée en une dose intracrânienne pour traiter des enfants atteints d’une forme typique de la maladie de Canavan","language":34,"languageDescription":"French (France)"}],"publicTitle":"CAN-GT","publicTitleTranslations":[],"shortTitle":"CD Olig001-101","secondaryIdentifyingNumbers":{"nctNumber":{"id":529517,"number":"NCT04833907"},"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"7","trialCategory":"2","justificationForTrialCategory":"The trial is a phase 1/2, therefore it corresponds to category 2.","trialCategoryId":119183},"medicalCondition":{"partIMedicalConditions":[{"id":135161,"medicalCondition":"Canavan Disease","medicalConditionTranslations":[],"isConditionRareDisease":true},{"id":135160,"medicalCondition":"Canavan disease","medicalConditionTranslations":[{"id":10795800,"uuid":"e8ec3a3b-1fee-45c0-be47-b3f3d900ee22","attributeTranslation":"Maladie de Canavan","language":34,"languageDescription":"French (France)"}],"isConditionRareDisease":true}],"meddraConditionTerms":[{"termId":100000072713,"version":"20.0","level":"PT","termName":"Canavan disease","classificationCode":"10067608","organClass":100000004850,"active":false}]},"trialObjective":{"trialScopes":[{"code":"5","trialScopeId":392995},{"code":"7","trialScopeId":392994},{"code":"4","trialScopeId":392993},{"code":"3","trialScopeId":392992}],"mainObjective":"Assess the effect of rAAV-OLIG001-ASPA on cerebrospinal fluid (CSF) NAA concentrations in children with Canavan disease as measured by biochemical assay","mainObjectiveTranslations":[{"id":10795822,"uuid":"ed2df753-252a-4a51-b0bb-7754512cf95b","attributeTranslation":"Évaluer la sécurité et la tolérabilité de rAAVOlig001-ASPA administré par voie intracrânienne chez des enfants atteints de la maladie de Canavan de présentation typique","language":10,"languageDescription":"French"}],"secondaryObjectives":[{"id":459717,"number":1,"secondaryObjective":"Assess the effect of rAAV-OLIG001-ASPA on myelination in children with Cavanan disease as measured by volumetric MRI.","secondaryObjectiveTranslations":[{"id":10795823,"uuid":"bfd5e389-3344-40ac-b64a-17d63403e06f","attributeTranslation":"Évaluer l’effet de rAAV-OLIG001-ASPA sur la myélinisation chez des enfants atteints de la maladie de Canavan, mesuré à l’aide d’une IRM volumétrique.","language":10,"languageDescription":"French"}]},{"id":459718,"number":2,"secondaryObjective":"Assess the effect of rAAV-OLIG001-ASPA on gross motor development in children with Cavanan disease as measured by GMFM compared to an external control group","secondaryObjectiveTranslations":[{"id":10795824,"uuid":"4fbfd17e-626c-4253-967c-33fd4d5e8859","attributeTranslation":"Évaluer l’effet de rAAV-OLIG001-ASPA sur le développement moteur global chez des enfants atteints de la maladie de Canavan, mesuré à l’aide du GMFM, par rapport à un groupe témoin externe.","language":10,"languageDescription":"French"}]},{"id":459719,"number":3,"secondaryObjective":"Assess the domain-specific effect of rAAV-OLIG001-ASPA on gross motor development in children with Cavanan disease as measured by GMFM compared to an external control group","secondaryObjectiveTranslations":[{"id":10795825,"uuid":"33774dbc-e66a-4969-a401-5d15c3382e97","attributeTranslation":"Évaluer l’effet spécifique à chaque domaine de rAAV-OLIG001-ASPA sur le développement moteur global chez des enfants atteints de la maladie de Canavan, mesuré à l’aide du GMFM, par rapport à un groupe témoin externe.","language":10,"languageDescription":"French"}]},{"id":459720,"number":4,"secondaryObjective":"Evaluate the overall effect of rAAV-OLIG001-ASPA on the developmental progress in children with Canavan disease compared to an external control group as measured by MSEL age-equivalent domain scores","secondaryObjectiveTranslations":[{"id":10795826,"uuid":"0a4a0db6-4a36-43ed-9a9f-6b5cfd940f82","attributeTranslation":"Évaluer l’effet global de rAAV-OLIG001-ASPA sur le développement d’enfants atteints de la maladie de Canavan par rapport à un groupe témoin externe, à l’aide des scores obtenus pour les domaines MSEL ajustés en fonction de l’âge.","language":10,"languageDescription":"French"}]},{"id":459721,"number":5,"secondaryObjective":"Evaluate the domain-specific effects of rAAV-OLIG001-ASPA on the developmental progress in children with Canavan disease compared to an external control group as measured by MSEL age-equivalent domain scores","secondaryObjectiveTranslations":[{"id":10795827,"uuid":"9d0b2bea-8952-408e-a7bc-58bae9ee3fa3","attributeTranslation":"Évaluer les effets spécifiques à chaque domaine de rAAV-OLIG001-ASPA sur le développement d’enfants atteints de la maladie de Canavan par rapport à un groupe témoin externe, mesurés par les scores obtenus pour les domaines MSEL ajustés en fonction de l’âge.","language":10,"languageDescription":"French"}]},{"id":459722,"number":6,"secondaryObjective":"Assess the effect of rAAV-OLIG001-ASPA on urine NAA concentration as measured by biochemical assay","secondaryObjectiveTranslations":[{"id":10795828,"uuid":"ef6f7757-a7be-438a-b3c2-57f001260fe7","attributeTranslation":"Évaluer l’effet de rAAV-OLIG001-ASPA sur la concentration de NAA dans l’urine, mesuré à l’aide d’un dosage biochimique.","language":10,"languageDescription":"French"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":876708,"number":1,"principalInclusionCriteria":"Definitive diagnosis of typical CD by a neurologist (see Section 3.2 of protocol for detailed description).","principalInclusionCriteriaTranslations":[{"id":10795818,"uuid":"597f4609-f266-453f-928e-b2bda724b728","attributeTranslation":"Diagnostic définitif d’une forme typique de la MC établi par un neurologue (voir la rubrique 3.2 du protocole pour une description détaillée).","language":10,"languageDescription":"French"}]},{"id":876709,"number":2,"principalInclusionCriteria":"Age between 3 and 60 months at the time of neurosurgical administration of rAAV- Olig001-ASPA or over the age of 60 months for untreated patients in Cohort 4.","principalInclusionCriteriaTranslations":[{"id":10795819,"uuid":"533e2504-9c46-4452-8df1-79999cf3f894","attributeTranslation":"Âge compris entre 3 et 60 mois au moment de l’administration neurochirurgicale de rAAV-Olig001-ASPA ou âge supérieur à 60 mois pour les patients non traités de la cohorte 4.","language":10,"languageDescription":"French"}]},{"id":876710,"number":3,"principalInclusionCriteria":"Written informed consent from parent(s)/guardian(s). Consent to enroll into the study will include a written agreement to comply with all the conditions of the study, including attendance at follow-up visits.","principalInclusionCriteriaTranslations":[{"id":10795820,"uuid":"dec1f80a-b286-4ee9-bb93-86cf21df4f3a","attributeTranslation":"Signature du formulaire de consentement éclairé par le(s) parent(s)/tuteur(s) légal(-aux). Le consentement à l’inclusion dans l’étude comprendra l’engagement par écrit à se soumettre à toutes les conditions de l’étude, y compris à se présenter aux visites de suivi.","language":10,"languageDescription":"French"}]},{"id":876711,"number":4,"principalInclusionCriteria":"MRI or CT within the past 3 months, for preliminary neurosurgical planning; if no MRI or CT within 3 months is available, MRI can be done during Screening assuming that the results of all other Inclusion/Exclusion Criteria are acceptable.","principalInclusionCriteriaTranslations":[{"id":10795821,"uuid":"d2e19411-439a-4b6f-822a-dc740e1bbece","attributeTranslation":"Examen IRM ou TDM au cours des 3 derniers mois destiné à préparer l’intervention de neurochirurgie. Si aucun résultat d’examen IRM ou TDM de moins de 3 mois n’est disponible, une IRM peut être réalisée au cours de la sélection, à condition que les résultats pour tous les autres critères d’inclusion/exclusion soient acceptables.","language":10,"languageDescription":"French"}]}],"principalExclusionCriteria":[{"id":1499209,"number":1,"principalExclusionCriteria":"At the discretion of the PI, any significant chronic medical condition, including, but not limited to neurological, cardiac, hepatic, renal, hematological, gastrointestinal, endocrine, pulmonary, or infectious disease, which would put the subject at increased risk during surgery or which would interfere with participation in the study, interpretation of safety monitoring, or the integrity of the study data.","principalExclusionCriteriaTranslations":[{"id":10795808,"uuid":"0b84469a-6794-4e34-b2d8-d671bbbb9fbb","attributeTranslation":"À la discrétion de l’IP, toute affection médicale chronique significative, y compris, sans s’y limiter, toute maladie neurologique, cardiaque, hépatique, rénale, hématologique, gastro-intestinale, endocrinienne, pulmonaire ou infectieuse, susceptible d’exposer le sujet à un risque accru lors de l’intervention chirurgicale ou d’interférer avec sa participation à l’étude, avec l’interprétation des données de sécurité d’emploi ou avec l’intégrité des données de l’étude.","language":10,"languageDescription":"French"}]},{"id":1499210,"number":2,"principalExclusionCriteria":"History of severe allergic reaction or anaphylaxis.","principalExclusionCriteriaTranslations":[{"id":10795809,"uuid":"601aa39f-0196-4d2d-b2b4-f0be9758eb81","attributeTranslation":"Antécédents de réaction allergique grave ou d’anaphylaxie.","language":10,"languageDescription":"French"}]},{"id":1499211,"number":3,"principalExclusionCriteria":"Past participation in gene therapy trials or receipt of any other investigational product within 6 months prior to enrollment.","principalExclusionCriteriaTranslations":[{"id":10795810,"uuid":"f7c3e19b-637a-4b95-9212-740882c8746e","attributeTranslation":"Participation antérieure à des essais de thérapie génique ou traitement par tout autre produit expérimental au cours des 6 mois précédant l’inclusion.","language":10,"languageDescription":"French"}]},{"id":1499212,"number":4,"principalExclusionCriteria":"Any absolute contraindication to immunosuppression.","principalExclusionCriteriaTranslations":[{"id":10795811,"uuid":"4e79cb67-da32-41b7-a00d-a339d66784a6","attributeTranslation":"Toute contre-indication absolue à l’administration d’immunosuppresseurs.","language":10,"languageDescription":"French"}]},{"id":1499213,"number":5,"principalExclusionCriteria":"Any absolute contraindication to MRI.","principalExclusionCriteriaTranslations":[{"id":10795812,"uuid":"9e994adb-b921-4ed8-bbea-d71db8efcaf5","attributeTranslation":"Toute contre-indication absolue à la réalisation d’IRM.","language":10,"languageDescription":"French"}]},{"id":1499214,"number":6,"principalExclusionCriteria":"Any vaccination less than 1 month prior to gene therapy.","principalExclusionCriteriaTranslations":[{"id":10795813,"uuid":"26c8b7b4-b948-4c09-a592-99d6cba8a1bb","attributeTranslation":"Toute vaccination moins d’un mois avant l’administration de la thérapie génique.","language":10,"languageDescription":"French"}]},{"id":1499215,"number":7,"principalExclusionCriteria":"Anticipated life expectancy of less than 12 months for any reason.","principalExclusionCriteriaTranslations":[{"id":10795814,"uuid":"ed59b83f-45f8-4f68-94d8-2bffa1a11e85","attributeTranslation":"Espérance de vie anticipée estimée à moins de 12 mois, quelle que soit la raison de cette estimation.","language":10,"languageDescription":"French"}]},{"id":1499216,"number":8,"principalExclusionCriteria":"GMFM-88 total raw score >35%.","principalExclusionCriteriaTranslations":[{"id":10795815,"uuid":"2f543989-b306-499b-a8e5-8882b92761fa","attributeTranslation":"Score brut total à l’évaluation GMFM-88 > 35 %.","language":10,"languageDescription":"French"}]},{"id":1499217,"number":9,"principalExclusionCriteria":"Clinically significant out-of-range lab values as indicated in Appendix G, at the discretion of clinical PI.","principalExclusionCriteriaTranslations":[{"id":10795816,"uuid":"d44a97dd-b5a6-4744-83e9-a0763f9eca27","attributeTranslation":"Résultats d’analyses biologiques sortant des normes de manière cliniquement significative, comme indiqué à l’annexe G, à la discrétion de l’IP clinicien.","language":10,"languageDescription":"French"}]}]},"endPoint":{"primaryEndPoints":[{"id":1026312,"number":1,"endPoint":"Change from baseline to Month 6 in CSF NAA concentrations, as measured by biochemical assay.","isPrimary":true,"endPointTranslations":[{"id":10795801,"uuid":"c11ff892-126b-4503-ac48-38ba4d72463c","attributeTranslation":"Variation de la concentration de NAA dans le LCS entre la référence et le mois 6, mesurée à l’aide d’un dosage biochimique.","language":10,"languageDescription":"French"}]}],"secondaryEndPoints":[{"id":1026313,"number":1,"endPoint":"Rate of change in myelin volume in the brain as measured by SyMRI through Month 12.","isPrimary":false,"endPointTranslations":[{"id":10795802,"uuid":"9607a4ed-1477-4bc5-aabb-fd076ac92fc7","attributeTranslation":"Le taux de variation du volume de myéline dans le cerveau mesuré à l’aide de la technique SyMRI jusqu’au mois 12.","language":10,"languageDescription":"French"}]},{"id":1026314,"number":2,"endPoint":"Rate of change from baseline in Gross Motor Function Measure-88 total score, comparing FIH gene therapy–treated cohort to an external natural history cohort.","isPrimary":false,"endPointTranslations":[{"id":10795803,"uuid":"84e89d36-8136-40ba-ad17-12fd869af4e7","attributeTranslation":"Taux de variation par rapport à la référence du score total de la Mesure de la fonction motrice globale à 88 éléments (Gross Motor Function Measure-88), comparant la cohorte traitée par thérapie génique utilisée pour la première fois chez l’humain par rapport à une cohorte externe constituée pour recueillir des données sur l’évolution naturelle de la maladie.","language":10,"languageDescription":"French"}]},{"id":1026315,"number":3,"endPoint":"Rate of change from baseline in Gross Motor Function Measure-88 specific domains, comparing FIH gene therapy–treated cohort to an external natural history cohort: - Lying/rolling domain - Sitting domain - Crawling domain - Standing domain - Walking domain","isPrimary":false,"endPointTranslations":[{"id":10795804,"uuid":"48fb1a68-43f4-4eac-98c7-62d120b6c633","attributeTranslation":"•\tTaux de variation par rapport à la référence des différents domaines de la Mesure de la fonction motrice globale à 88 éléments, comparant la cohorte traitée par thérapie génique utilisée pour la première fois chez l’humain par rapport à une cohorte externe constituée pour recueillir des données sur l’évolution naturelle de la maladie :\n- Domaine Se coucher et rouler\n- Domaine S’asseoir\n- Domaine Ramper\n- Domaine Se mettre debout\n- Domaine Marcher","language":10,"languageDescription":"French"}]},{"id":1026316,"number":4,"endPoint":"Rate of change from baseline in multivariate MSEL domains age-equivalent scores compared with an external natural history cohort.  MSEL domains include: Visual Reception, Fine Motor, Receptive Language, Expressive Language, Gross Motor","isPrimary":false,"endPointTranslations":[{"id":10795805,"uuid":"4918e5bd-1889-4522-82d5-b0bf6e702711","attributeTranslation":"Taux de variation par rapport à la référence des scores multivariés obtenus pour les domaines MSEL ajustés en fonction de l’âge par rapport à une cohorte externe constituée pour recueillir des données sur l’évolution naturelle de la maladie. \nLes domaines MSEL comprennent : réception visuelle, motricité fine, langage réceptif, langage expressif, motricité brute.","language":10,"languageDescription":"French"}]},{"id":1026317,"number":5,"endPoint":"Rate of change from baseline in univariate MSEL domains age-equivalent scores compared with an external natural history cohort:  -       MSEL Receptive Language domain  -       MSEL Expressive Language domain  -       MSEL Visual Reception domain  -       MSEL Fine Motor domain   -    MSEL  -       Gross Motor domain","isPrimary":false,"endPointTranslations":[{"id":10795806,"uuid":"6556d034-7e17-4cb9-9126-862c68415b74","attributeTranslation":"Taux de variation par rapport à la référence des scores univariés obtenus pour les domaines MSEL ajustés en fonction de l’âge par rapport à une cohorte externe constituée pour recueillir des données sur l’évolution naturelle de la maladie : \n-       Domaine MSEL Langage réceptif\n-       Domaine MSEL Langage expressif\n-       Domaine MSEL Réception visuelle\n-       Domaine MSEL Motricité fine\n-     Domaine MSEL Motricité brute","language":10,"languageDescription":"French"}]},{"id":1026318,"number":6,"endPoint":"Change from baseline to Month 6 in urine NAA concentrations, as measured by biochemical assays","isPrimary":false,"endPointTranslations":[{"id":10795807,"uuid":"cbdd902a-02bc-4fa1-87ed-9c5beec21a1c","attributeTranslation":"Variation de la concentration de NAA dans l’urine entre la référence et le mois 6, mesurée à l’aide d’un dosage biochimique.","language":10,"languageDescription":"French"}]}]},"trialDuration":{"estimatedGlobalEndDate":"2031-04-30","estimatedEndDate":"2031-04-30","estimatedRecruitmentStartDate":"2026-02-01"},"sourceOfMonetarySupport":[{"id":94888,"organisationName":"Myrtelle, Inc."}],"populationOfTrialSubjects":{"ageRanges":[{"id":355792,"ageRangeCategoryCode":"2","ageRangeCategory":"2"}],"ageRangeSecondaryIds":[{"id":355795,"ageRangeCategoryCode":"2","ctAgeRangeCode":"4","ageRangeCategory":"2","ctAgeRange":"4"},{"id":355794,"ageRangeCategoryCode":"2","ctAgeRangeCode":"5","ageRangeCategory":"2","ctAgeRange":"5"},{"id":355793,"ageRangeCategoryCode":"2","ctAgeRangeCode":"3","ageRangeCategory":"2","ctAgeRange":"3"}],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":true},"individualParticipantData":{"planToShareIPD":"2"}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[{"id":11577,"paediatricInvestigationNumber":"EMEA-003459-PIP01-23"}]},"associatedClinicalTrials":[],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-06-12","conclusionDate":"2026-06-12","therapeuticAreas":[{"code":"16","name":"Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]"}],"medicalConditions":[{"id":135161,"medicalCondition":"Canavan Disease","isConditionRareDisease":true},{"id":135160,"medicalCondition":"Canavan disease","isConditionRareDisease":true}],"sponsors":[{"id":147002,"primary":true,"publicContacts":[{"id":433713,"type":"Public","functionalName":"Olga Flamini","functionalEmailAddress":"oflamini@myrtellegtx.com","telephone":"+13024010206","organisation":{"id":679856,"type":"Pharmaceutical company","typeCode":"10","name":"Myrtelle Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100051738","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":433714,"type":"Scientific","functionalName":"Olga Flamini","functionalEmailAddress":"oflamini@myrtellegtx.com","telephone":"+13024010206","organisation":{"id":679856,"type":"Pharmaceutical company","typeCode":"10","name":"Myrtelle Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100051738","organisationLocationStatus":"Active"}}],"thirdParties":[{"id":664496,"organisationAddress":{"id":803522,"organisation":{"id":842797,"type":"Health care","typeCode":"2","name":"Kennedy Krieger Institute","commercial":false,"isBusinessKeyValidated":false,"businessKey":"ORL-000015293","organisationLocationStatus":"Active"},"address":{"addressId":889138,"oneLine":"707 N Broadway","addressLine1":"707 N Broadway","addressLine2":"","addressLine3":"","addressLine4":"","city":"Baltimore","postcode":"21205","country":840,"countryName":"United States"},"phone":"+14439232782","email":"kratz@kennedykrieger.org","isBusinessKeyValidated":false,"businessKey":"ORL-000015293"},"sponsorDuties":[{"id":1031453,"code":"15","value":"NAA Analysis in CSF and Urine"},{"id":1031454,"code":"4"}],"phoneNumber":"+14439232782","email":"kratz@kennedykrieger.org"},{"id":664499,"organisationAddress":{"id":704860,"organisation":{"id":743067,"type":"Pharmaceutical company","typeCode":"10","name":"Voisin Consulting CH SARL","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100031396","organisationLocationStatus":"Active"},"address":{"addressId":771081,"oneLine":"Innovation Park Batiment F, Epfl","addressLine1":"Innovation Park Batiment F","addressLine2":"Epfl","addressLine3":"","addressLine4":"","city":"Lausanne","postcode":"1015","country":756,"countryName":"Switzerland"},"phone":"+41215470431","email":"brehm@voisinconsulting.com","isBusinessKeyValidated":true,"businessKey":"ORG-100031396"},"sponsorDuties":[{"id":1031457,"code":"1"},{"id":1031458,"code":"11"},{"id":1031459,"code":"12"},{"id":1031460,"code":"15","value":"Trial Master File management"},{"id":1031461,"code":"5"},{"id":1031462,"code":"6"},{"id":1031463,"code":"7"},{"id":1031464,"code":"8"}],"phoneNumber":"+41215470431","email":"brehm@voisinconsulting.com"},{"id":664500,"organisationAddress":{"id":705175,"organisation":{"id":743386,"type":"Pharmaceutical company","typeCode":"10","name":"Parexel International (IRL) Limited","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100022780","organisationLocationStatus":"Active"},"address":{"addressId":771456,"oneLine":"70 Sir John Rogerson's Quay","addressLine1":"70 Sir John Rogerson's Quay","addressLine2":"","addressLine3":"","addressLine4":"","city":"Dublin 2","postcode":"D02 R296","country":2017,"countryName":"Ireland"},"phone":"+35314739500","email":"Clinicaltrial.Enquiries@parexel.com","isBusinessKeyValidated":true,"businessKey":"ORG-100022780"},"sponsorDuties":[{"id":1031465,"code":"10"}],"phoneNumber":"+35314739500","email":"Clinicaltrial.Enquiries@parexel.com"},{"id":664497,"organisationAddress":{"id":704863,"organisation":{"id":743070,"type":"Pharmaceutical company","typeCode":"10","name":"Kcas LLC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100043073","organisationLocationStatus":"Active"},"address":{"addressId":771085,"oneLine":"10830 South Clay Blair Boulevard","addressLine1":"10830 South Clay Blair Boulevard","addressLine2":"","addressLine3":"","addressLine4":"","city":"Olathe","postcode":"66061-1309","country":840,"countryName":"United States"},"phone":"+19132483096","email":"melissa.mcadams@kcasbio.com","isBusinessKeyValidated":true,"businessKey":"ORG-100043073"},"sponsorDuties":[{"id":1031455,"code":"4"}],"phoneNumber":"+19132483096","email":"melissa.mcadams@kcasbio.com"},{"id":664498,"organisationAddress":{"id":704864,"organisation":{"id":743071,"type":"Pharmaceutical company","typeCode":"10","name":"Perceptive Informatics Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100013171","organisationLocationStatus":"Active"},"address":{"addressId":771086,"oneLine":"55 Blue Sky Drive","addressLine1":"55 Blue Sky Drive","addressLine2":"","addressLine3":"","addressLine4":"","city":"Burlington","postcode":"01803-2775","country":840,"countryName":"United States"},"phone":"+15107103362","email":"mneustadt@invicro.com","isBusinessKeyValidated":true,"businessKey":"ORG-100013171"},"sponsorDuties":[{"id":1031456,"code":"15","value":"SyMRI"}],"phoneNumber":"+15107103362","email":"mneustadt@invicro.com"},{"id":664495,"organisationAddress":{"id":704865,"organisation":{"id":743072,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"Mural Health Technologies Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100051510","organisationLocationStatus":"Active"},"address":{"addressId":771087,"oneLine":"1189 Lancaster Avenue","addressLine1":"1189 Lancaster Avenue","addressLine2":"","addressLine3":"","addressLine4":"","city":"Berwyn","postcode":"19312-1299","country":840,"countryName":"United States"},"phone":"+12675500944","email":"courtney@muralhealth.com","isBusinessKeyValidated":true,"businessKey":"ORG-100051510"},"sponsorDuties":[{"id":1031452,"code":"15","value":"Patient reimbursement and patient level"}],"phoneNumber":"+12675500944","email":"courtney@muralhealth.com"}],"organisation":{"id":679856,"type":"Pharmaceutical company","typeCode":"10","name":"Myrtelle Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100051738","organisationLocationStatus":"Active"},"addresses":[{"id":641895,"organisation":{"id":679856,"type":"Pharmaceutical company","typeCode":"10","name":"Myrtelle Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100051738","organisationLocationStatus":"Active"},"address":{"addressId":695795,"oneLine":"17 State Street","addressLine1":"17 State Street","addressLine2":"","addressLine3":"","addressLine4":"","city":"New York","postcode":"10004-1501","country":840,"countryName":"United States"},"isBusinessKeyValidated":true,"businessKey":"ORG-100051738"}],"isCommercial":true,"commercial":"Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"The trial is a phase 1/2, therefore it corresponds to category 2.","partOneTherapeuticAreas":[{"id":1154209,"therapeuticArea":{"code":"16","name":"Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]"}}],"productRoleGroupInfos":[{"id":401067,"comments":"rAAV-Olig001-ASPA","productRoleCode":"1","productRoleName":"Test","products":[{"id":538112,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11718547","productPharmForm":"SOLUTION FOR INJECTION","euMpNumber":"PRD11718547","prodAuthStatus":1,"prodName":"rAAV-Olig001-ASPA","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"CIRACIGENE GOLPARVOVEC","euSubstNumber":"SUB284340","productOtherName":"ciracigene golparvovec","nameOrg":"MYRTELLE, INC.","productSubstances":[{"productPk":"11718547","substancePk":"404900","nameOrg":"MYRTELLE, INC.","substanceOrigin":"Structurally Diverse Substance - Other","actSubstOrigin":"Structurally Diverse Substance - Other","actSubstName":"CIRACIGENE GOLPARVOVEC","substanceEvCode":"SUB284340","synonyms":["MYR-101","Recombinant adeno-associated virus Olig001 containing human aspartoacylase cDNA","rAAV-Olig001 containing human ASPA cDNA"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/22/2729","evCode":"PRD11718547","sponsorProductCodeEdit":"MYR-101","therapies":[{"id":6861,"catReferenceNumber":"EMA/CAT/638421/2022","advancedTherapyType":"3","geneOfInterest":"ASPA","description":"The product contains recombinant adeno- associated virus capsid and a genetic component containing the human ASPA cDNA (rAAV- ASPA).","isGmo":false,"isInVivo":true,"geneTransferProductType":"3"}],"devices":[],"characteristics":["8"],"routes":["INTRACEREBROVENTRICULAR (ICV)"],"allSubstancesChemicals":false,"productName":"rAAV-Olig001-ASPA","jsonActiveSubstanceNames":"ciracigene golparvovec","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":284071,"mscId":45700,"mscInfo":{"id":45700,"clinicalTrialId":20676,"countryOrganisationId":2012,"reportingStatusCode":"Authorised","fromDate":"2026-02-03","toDate":"2026-02-03","isProposedRms":true,"countryName":"France","organisationInfo":{},"firstDecisionDate":"2026-02-18","trialStatus":"Authorised","trialPeriod":[{"id":89834,"trialStartDate":"2026-09-02","fromDate":"2026-09-10"},{"id":89835,"trialStartDate":"2026-09-02","fromDate":"2026-09-10"}],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{"id":151381,"trialStartDate":"2026-09-02","fromDate":"2026-09-10"},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":102003,"mscId":45700,"trialStatus":"Under evaluation","trialStatusDate":"2025-10-10T11:25:52.146"},{"id":292960,"mscId":45700,"trialStatus":"Authorised","trialStatusDate":"2026-02-18T18:26:43.843"}],"applicationTypeMsc":"1","mscName":"France","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-04-07","decision":"authorized_conditions","decisionDate":"2026-02-18"},"decisionDate":"2026-02-18","recruitmentSubjectCount":7,"trialSites":[{"id":1956200,"organisationAddressInfo":{"id":708413,"organisation":{"id":746632,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Bicetre Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028802","organisationLocationStatus":"Active"},"address":{"addressId":775164,"oneLine":"78 Rue Du General Leclerc","addressLine1":"78 Rue Du General Leclerc","addressLine2":"","addressLine3":"","addressLine4":"","city":"Le Kremlin Bicetre Cedex","postcode":"94275","country":2012,"countryName":"France"},"phone":"+330145213017","email":"caroline.sevin@icm-institute.org","isBusinessKeyValidated":true,"businessKey":"ORG-100028802"},"personInfo":{"id":2172762,"firstName":"Caroline","lastName":"Sevin","telephone":"+330145213017","email":"caroline.sevin@icm-institute.org"},"departmentName":"Service de Neurologie Pédiatrique"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":39819,"type":"INITIAL","status":"Authorised","ctNumber":"2024-519412-13-00","trialStatus":"Authorised","submissionDate":"2025-10-10","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-02-13"},"partIIInfo":[{"id":277586,"mscId":45700,"mscInfo":{"id":45700,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2026-02-04","decision":"authorized_conditions","decisionDate":"2026-02-18","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2026-02-18"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-02-18","ctMSCsByApplication":[{"id":45700,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":110512,"applicationId":39819,"mscId":45700,"mscName":"France","decisionDate":"2026-02-18T18:26:44.216","decision":"authorized_conditions","assessmentOutcome":"acceptable_conditions","eventType":"decision","part2Id":277586,"part1Id":116940,"applicationType":"INITIAL","isRMS":true}]},{"id":78107,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-519412-13-00","trialStatus":"Authorised","submissionDate":"2026-02-26","partI":{"assessmentOutcome":"acceptable"},"partIIInfo":[{"id":284071,"mscId":45700,"mscInfo":{"id":45700,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-04-07","decision":"authorized_conditions","decisionDate":"2026-02-18","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2026-02-18"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-04-07","ctMSCsByApplication":[{"id":45700,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"SM-1","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":117615,"applicationId":78107,"mscId":45700,"mscName":"France","decisionDate":"2026-04-07T08:54:11.047","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":284071,"part1Id":119720,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]},{"id":84645,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-519412-13-00","trialStatus":"Authorised","submissionDate":"2026-05-18","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-06-12"},"partIIInfo":[],"decisionDate":"2026-06-12","ctMSCsByApplication":[{"id":45700,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"SM-2","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":128448,"applicationId":84645,"mscId":45700,"mscName":"France","decisionDate":"2026-06-12T17:01:07.297","decision":"authorized","eventType":"decision","part1Id":129561,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"France","mscId":45700,"firstDecisionDate":"2026-02-18T18:26:44.216","lastDecisionDate":"2026-04-07T08:54:11.047","mscPublicStatusCode":3}],"eudraCt":{"isTransitioned":false}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":45700,"mscName":"France","events":[{"notificationType":"START_OF_TRIAL","date":"2026-09-02"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"K1_Recruitement arrangements_FR","uuid":"fcb780a8-9e24-4a41-adee-c752aa06c875","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":284071,"manualVersion":"N/A","systemVersion":"1"},{"title":"K2_Document additionel_FR_Redacted","uuid":"4dd76fed-a754-43de-8f21-40e2de00179d","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":284071,"manualVersion":"N/A","systemVersion":"1"},{"title":"L1_SIS and  ICF_Main_Cohort 4_FR_redacted","uuid":"b1fd8509-9f44-4419-88a4-0ff074ec9072","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":284071,"manualVersion":"4.0","systemVersion":"4"},{"title":"L1_SIS and  ICF_Main_Cohort 1 to 3_FR_redacted","uuid":"f869684c-c941-47a5-9bdf-9ae02506370b","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":284071,"manualVersion":"4.0","systemVersion":"4"},{"title":"D1_Protocol_2024-519412-13-00_redacted","uuid":"f1d0fa8a-b42d-4ad9-a223-1bd75342b917","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":129561,"manualVersion":"11.1","systemVersion":"3"},{"title":"D1_Lay Language Synopsis_EN_2024-519412-13-00","uuid":"3e111045-be29-4471-a79e-4fac57a1acba","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":129561,"manualVersion":"2.0","systemVersion":"3"},{"title":"D1_Lay Language Synopsis_FR_2024-519412-13-00","uuid":"2074c1f3-ee19-4540-b988-1cc80f2e390a","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":129561,"manualVersion":"2.0","systemVersion":"3"}],"trialRegion":"Both","trialRegionCode":3,"correctiveMeasures":[]}